{"id":235617,"date":"2026-06-15T00:00:00","date_gmt":"2026-06-15T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041106-medtech-hyaluronic-acid-viscosupplementation-market\/"},"modified":"2026-06-17T11:04:38","modified_gmt":"2026-06-17T11:04:38","slug":"48000655-medtech-hyaluronic-acid-viscosupplementation-market-insights-global","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/48000655-medtech-hyaluronic-acid-viscosupplementation-market-insights-global\/","title":{"rendered":"Hyaluronic Acid Viscosupplementation &#8211; Market Insights &#8211; Global"},"content":{"rendered":"<p>The global <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> viscosupplementation market will <span>grow modestly<\/span> over the forecast period. This growth will be supported by an aging population and a rising number of people with <abbr data-abbreviation-entity=\"10881\" title=\"Osteoarthritis\">OA<\/abbr>. Better patient awareness, improved physician experience with injections, and product improvements will also help maintain demand. Although alternative treatment options are becoming popular, increasing clinical evidence showing that <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injections can help reduce <abbr data-abbreviation-entity=\"10881\" title=\"Osteoarthritis\">OA<\/abbr> pain will continue to support their use. While 1-injection <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> products, which are more expensive, will gain traction due to their convenience for patients and physicians, 3- and 5-injection products will remain widely used in some countries due to lower costs, easier access, and favorable reimbursement.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the state of the market for <abbr title=\"Hyaluronic Acid\">HA<\/abbr> viscosupplementation in the US, Europe, Asia Pacific, and Brazil from 2019 through 2035.<\/p>\n<p><strong>Increasing awareness about the treatment among physicians and patients will support the <abbr title=\"Hyaluronic Acid\">HA<\/abbr> viscosupplementation market.<\/strong><\/p>\n<p>How does increasing physician awareness of <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> therapy influence prescribing behavior?<\/p>\n<p>Can improved patient understanding of the benefits of <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> viscosupplementation accelerate earlier treatment use?<\/p>\n<p>How does rising awareness help <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injections remain relevant amid competing therapies?<\/p>\n<p><strong>In Europe, knee <abbr data-abbreviation-entity=\"10881\" title=\"Osteoarthritis\">OA<\/abbr> patients are increasingly managing symptoms with <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injections instead of immediate surgical intervention.<\/strong><\/p>\n<div>What factors influence treatment choices for knee <abbr data-abbreviation-entity=\"10881\" title=\"Osteoarthritis\">OA<\/abbr> patients when deciding between surgery and injectable therapies?<\/div>\n<p>Does faster access in private care increase demand for premium <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injections?<\/p>\n<div>What role do <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> viscosupplementation injections play as part of longterm knee <abbr data-abbreviation-entity=\"10881\" title=\"Osteoarthritis\">OA<\/abbr> symptom management?<\/div>\n<p><strong>In China, demand is rising for more convenient, fewervisit <abbr data-abbreviation-entity=\"10881\" title=\"Osteoarthritis\">OA<\/abbr> treatments.<\/strong><\/p>\n<p>How does the availability of a new 1injection <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> option influence physician prescribing patterns in China?<\/p>\n<p>What impact will <abbr data-abbreviation-entity=\"10592\" title=\"Volume-Based Procurement\">VBP<\/abbr> have on <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injections in China?<\/p>\n<p>How will wider uptake of 1injection <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr>\u00a0products affect the use of multiinjection <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> and other nonsurgical treatments?<\/p>\n<p><strong>Broad professional acceptance within the orthopedic community will continue to support increased use of HA injection procedures.<\/strong><strong> <\/strong><\/p>\n<div>\n<p>How important are consensus guidelines in sustaining <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injection growth in the Brazilian market?<\/p>\n<p>What will support continued use of <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injections in both public and private orthopedic practice?<\/p>\n<p>How do physician treatment preferences dictate the selection of <abbr data-abbreviation-entity=\"8852\" title=\"Hyaluronic Acid\">HA<\/abbr> injection regimens in Brazil?<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-235617","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-orthopedics","medtech-date-2828"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/235617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=235617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}